AbbVie | ABBV - Loan Capital


AbbVie reported $64.53B in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
AbbVie USD 64.53B 5.59B Mar/2026
Abbott USD 29.64B 19.74B Mar/2026
ALKERMES USD 1.48B 7.23M Jun/2026
Amgen USD 51.86B 27M Jun/2026
AstraZeneca USD 26.01B 46M Jun/2026
Biogen USD 7.29B 1B Jun/2026
BioMarin Pharmaceutical USD 3.53B 2.1B Jun/2026
Bristol-Myers Squibb USD 42.09B 59M Jun/2026
Coherus Biosciences USD 51.08M 496K Dec/2025
Eisai JPY 184.6B 49.83B Jun/2026
Eli Lilly USD 47.86B 8.49B Jun/2026
Gilead Sciences USD 20.86B 1.27B Mar/2026
GlaxoSmithKline GBP 13.95B 65M Jun/2026
J&J USD 37.34B 183M Jun/2026
Medtronic USD 27.88B 255M Dec/2025
Merck USD 51.08B 4.41B Jun/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 37.49B 42M Jun/2026
Pacira USD 363.12M 4.53M Jun/2026
Perrigo USD 3.28B 337.7M Jun/2026
Pfizer USD 60.5B 70M Jun/2026
Regeneron Pharmaceuticals USD 1.99B 400K Jun/2026
Roche Holding CHF 25.22B 2.21B Jun/2026
Sanofi EUR 14.65B 806M Jun/2026
UCB EUR 2.18B 634M Dec/2025
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
United Therapeutics USD 100M 100M Jun/2024
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025
Zoetis USD 9.05B 3M Jun/2026